Major cell-based therapy randomised controlled trials
| Origin | Cell type | Trial name | Phase | Administration | Patient cohort | Number of participants | Main effect |
|---|---|---|---|---|---|---|---|
| BM | MNC | REPAIR-AMI44 | II | IC | AMI + PCI | 204 | Improved LVEF, decreased mortality |
| ASTAMI46 | II | IC | AMI + PCI | 97 | Negative | ||
| BELGIUM47 | II | IC | AMI + PCI | 67 | Reduced scar size but no difference in myocardial perfusion | ||
| BOOST48 | II | IC | AMI + PCI | 60 | Improved EF in short term with a single dose | ||
| TIME/Late TIME53 54 | II | IC | AMI + PCI | 120 | Negative for LV function and infarct size | ||
| Cao et al105 | I/II | IC | AMI + PCI | 86 | Safe, improved EF but similar myocardial perfusion to placebo | ||
| FINCELL52 | I/II | IC | AMI + PCI | 80 | Safe, improved EF | ||
| HEBE50 | II | IC | AMI + PCI | 200 | Negative | ||
| BONAMI51 | II | IC | AMI + PCI | 101 | Improved LV viability on SPECT imaging | ||
| Hu et al56 | II | IM | ICM + CABG | 60 | Improved LV function and exercise tolerance | ||
| FOCUS-CCTRN57 | II | IM PC | ICM no option | 92 | Negative | ||
| Pokushalov et al58 | II | IM PC | ICM no option | 109 | Improved mortality, LV function, HF symptoms at 12-month | ||
| CELLWAVE59 | I/II | IC | ICM no option | 103 | Improved LVEF and contractility, delivery of cells following shockwave | ||
| CD34+ | Patel et al64 | I/II | IM | ICM +CABG | 20 | Improved LV function | |
| REGENT62 | II | IC | AMI + PCI | 200 | Negative | ||
| Losordo et al66 | II | IM PC | Angina no option | 167 | Improved exercise time, reduced CP frequency | ||
| ALDH+ | Perin et al63 | I/II | IM PC | ICM no option | 20 | Improved LVESV, potentially improved myocardial perfusion and oxygen consumption | |
| MSC | Chen et al69 | I/II | IC | AMI + PCI | 69 | Improved LV function and myocardial perfusion | |
| Chen et al70 | I/II | IC | ICM + PCI | 45 | Improved LV function, exercise time, symptoms and myocardial perfusion | ||
| Prochymal allogeneic71 | I/II | Intravenous | AMI + PCI | 53 | Improved EF | ||
| POSEIDON72 | I/II | IM PC | ICM no option | 30 | Autologous cells improved exercise time, allogeneic cells reduced LVESV | ||
| C-CURE | I/II | IM PC | ICM no option | 47 | Safe, improved LVEF, exercise tolerance, and performance | ||
| Fat | MSC | APOLLO75 | I | IC | AMI + PCI | 13 | Improved perfusion and reduced scar size |
| PRECISE76 | I | IC | ICM no option | 27 | Safe. Improved oxygen consumption and reduced scar size. | ||
| Heart | CDC | CADUCEUS85 | I | IC | Recent MI | 25 | Reduced scar size |
| c-kit | SCIPIO84 | I | IC | ICM no option | 16 | Improved LV function and reduced scar size |
ALDH, alcohol dehydrogenase; AMI, acute myocardial ischaemia; BM, bone marrow; CABG, coronary artery bypass graft; CDC, cardiosphere-derived cells; EF, ejection fraction; HF, heart failure; IC,intracoronary; ICM, ischaemic cardiomyopathy; IM, intramyocardial; LV, left ventricular; LVESV, left ventricular end-systolic volume; MNC, mononuclear cells; MSC, mesenchymal stem cells; PC, percutaneous; PCI, percutaneous coronary intervention.